Big Pharma Likes Big Trials, Biotech CEO Says; Tufts Defends R&D Estimate
Executive Summary
Large pharmaceutical companies are comfortable with high R&D costs because they create a barrier to entry in the industry, Cancer Therapeutics, Inc. CEO Robert Oldham, MD, maintained during a Capitol Hill briefing sponsored by the Manhattan Institute June 3
You may also be interested in...
FDA’s Autologous Cell Therapy Stance Needs Clarification, CTI Says
FDA needs to address the "unique aspects" of property rights involved in the medical use of autologous cell therapy, Cancer Therapeutics, Inc. told the agency in an exchange of letters regarding the regulatory status of CTI's research programs
FDA’s Autologous Cell Therapy Stance Needs Clarification, CTI Says
FDA needs to address the "unique aspects" of property rights involved in the medical use of autologous cell therapy, Cancer Therapeutics, Inc. told the agency in an exchange of letters regarding the regulatory status of CTI's research programs
Cancer Therapeutics Gets CBER Warning Letter For Website IND Descriptions
Cancer Therapeutics will keep descriptions of its investigational products on its website despite an FDA warning letter requesting their removal